HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB: ARDM) ("Aradigm" or the "Company") today
announced that the United States Patent and Trademark Office has issued
an important method of treatment patent (U.S. Patent No. 8,256,433)
covering Systems and Methods for Effecting Cessation of Tobacco Use. The
Company expects that the patent will provide exclusivity for specific
systems utilizing inhaled nicotine formulations until January 7, 2024.
"Tobacco smoking remains an enormous healthcare problem in the U.S.
which we believe is entirely preventable," said Igor Gonda, Aradigm's
President and CEO. "The craving for cigarettes has been documented to be
a key factor causing the high failure rate of currently approved
pharmaceutical approaches to smoking cessation. Several key opinion
leaders believe that the ideal smoking cessation tool should emulate the
delivery of nicotine by cigarettes — i.e., a true lung delivery that
provides a very rapid uptake of nicotine into the arterial blood similar
to that resulting from smoking cigarettes. Aradigm has developed the
AERX™ Nicotine Inhaler, an inhalation system which addresses this
critical product attribute and, in contrast to cigarettes, delivers pure
nicotine dissolved in water."
Aradigm has two issued U.S. patents, 6,799,576 and 6,874,507 covering
systems for effecting smoking cessation, which provide exclusivity until
2019. This newly issued patent is from a second patent family and
provides protection until at least 2024, greatly extending the duration
of protection. The first two patents are method of treatment patents,
covering systems, devices and containers for delivering aerosolized
nicotine formulations in specific ways which the Company believes to be
important for cigarette smokers who want to quit smoking. This new
patent extends the coverage to containers with novel features
anticipated to provide additional smoking cessation benefits.
About the AERx Nicotine Inhaler for Smoking Cessation
Aradigm's palm-size AERx Nicotine Inhaler generates a fine nicotine mist
from a solution of pure nicotine salt dissolved in a small amount of
water. No heating is used and there is no "secondhand smoke" as the user
takes a single deep inhalation from the inhaler, rather than "puffing"
on it. Phase I clinical results in smokers from the Company's inhaled
nicotine product candidate demonstrate cigarette-like nicotine
concentrations with nearly instantaneous high plasma levels of nicotine
and a rapid and lasting reduction in the craving for cigarettes.
Aradigm is an emerging specialty pharmaceutical company focused on the
development and commercialization of drugs delivered by inhalation for
the treatment of severe respiratory diseases by pulmonologists. The
Company has product candidates addressing the treatment of
bronchiectasis, cystic fibrosis, inhalation tularemia and anthrax
infections, and smoking cessation.
More information about Aradigm can be found at www.aradigm.com.
Except for the historical information contained herein, this news
release contains forward-looking statements that involve risk and
uncertainties, including the timing and results of future clinical
trials and treatment effectiveness of the Company's formulations, as
well as the other risks detailed from time to time in the Company's
filings with the Securities and Exchange Commission (SEC), including the
Company's Annual Report on Form 10-K for the year ended December 31,
2011 filed with the SEC on March 28, 2012, and the Company's Quarterly
Reports on Form 10-Q.
Aradigm, AERx and the Aradigm Logo are registered trademarks of Aradigm
Nancy Pecota, 510-265-8800
Source: Aradigm Corporation
News Provided by Acquire Media